Lisbon

• A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/ … Not authorised
  2022-500410-26-00 5 Cystic Fibrosis
• Phase2, double-blind, randomized, placebo-controlled, multicentre study to evaluation the safety, efficacy, and pharmacokinetics of TAK-242 … Not authorised
  2022-501026-37-00 4 ACLF is a syndrome that occurs in patients with chronic liver disease,
• Phase 3 Study Assessing Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit) Not authorised
  2022-501535-16-00 5 Atopic Dermatitis (AD)
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Unknown
  2022-502779-40-99 5 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• A clinical study of MK-7240 for the treatment of ulcerative colitis (MK-7240-001) Unknown
  2025-523766-25-00 5 Ulcerative colitis
• A study to investigate efficacy and safety with pegtibatinase compared to placebo in participants ≥12 to ≤65 years of age with classical hom … Pending
  2023-504135-40-00 5 Classical Homocystinuria
• Extension Study of ACT-EARLY Pending
  2024-513676-18-00 5 Transthyretin Amyloidosis
• EdoxabaN foR IntraCranial Hemorrhage survivors with Atrial Fibrillation Pending
  2024-518508-31-00 6 High risk atrial fibrillation patients with previous intracranial hemo
• An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH). Pending
  2024-520218-23-00 10 Pulmonary Arterial Hypertension
• A Study to Assess the Safety of RG6496 in Huntington’s Disease Gene Expansion Carriers with the Selected Genetic Variant (POINT-HD) Pending
  2025-520631-17-00 1 Huntington’s Disease Gene Expansion Carriers
• A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease Pending
  2025-521113-13-00 10 Early Parkinson’s Disease
• Phase 3 trial of VMX-C001 vs usual pharmacological care in patients taking a FXa direct oral anticoagulant who require urgent surgery with o … Pending
  2025-521632-12-00 5 Patients on Factor Xa inhibitor treatment needing an urgent interventi
• An Open-Label Study of ML-007C-MA in Adults with Alzheimer’s Disease Psychosis Pending
  2025-521757-16-00 4 Hallucinations and Delusions Associated with Alzheimer’s Disease Psych
• A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with In … Pending
  2025-521769-29-00 5 Pulmonary Hypertension Associated with Interstitial Lung Disease
• A Study to Investigate Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis (KATALYST-AV) Pending
  2025-522176-86-01 5 Moderate Calcific Aortic Valve Stenosis (CAVS)
• A Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis. Pending
  2025-522373-10-00 5 Progressive pulmonary fibrosis and Idiopathic pulmonary fibrosis
• A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P … Pending
  2025-522471-28-00 5 psoriatic arthritis (PsA)
• A Phase 3, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib in Subjects with Active Pso … Pending
  2025-522586-30-00 5 Psoriatic Arthritis
• A Phase 3 extension study to assess the long-term safety and efficacy of remibrutinib in adult participants with moderate to severe hidraden … Pending
  2025-523259-72-00 5 Hidradenitis Suppurativa (HS)
• Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis Pending
  2025-523400-72-00 4 Cystic fibrosis
• Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome Pending
  2025-523835-20-00 7 Dravet Syndrome
• Exogenous progesterone as ovulation trigger – a pilot study Pending
  2025-523850-15-00 6 Infertility
• A study in people with advanced extrapulmonary neuroendocrine cancer to compare obrixtamig plus carboplatin and etoposide treatment with sta … Pending
  2025-523869-22-00 5 advanced or metastatic extrapulmonary neuroendocrine carcinoma
• A Phase 3 Study of Orelabrutinib in Non-active Secondary Progressive Multiple Sclerosis Pending
  2025-524322-18-00 5 Non-active Secondary Progressive Multiple Sclerosis (SPMS)

Showing 1–24 of 608 trials